
    
      Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab
      combination therapy or SoC therapy. The primary objective of this study is to assess the
      efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in
      patients.
    
  